NasdaqGS - Nasdaq Real Time Price
USD
BioNTech SE (BNTX)
99.35
+1.81
(+1.86%)
At close: May 4 at 4:00:01 PM EDT
99.03
-0.32
(-0.32%)
Overnight: 2:07:43 AM EDT
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Trade BNTX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for BNTX
Chart does not reflect overnight price.
- Previous Close
97.54 - Open
98.88 - Bid 98.74 x 800
- Ask 99.67 x 800
- Day's Range
97.95 - 100.21 - 52 Week Range
79.52 - 124.00 - Volume
1,044,285 - Avg. Volume
1,111,020 - Market Cap (intraday)
25.124B - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
-- - EPS (TTM)
-5.61 - Earnings Date May 5, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 2, 2022
- 1y Target Est
130.44
Recent News: BNTX
View More
Performance Overview: BNTX
Trailing total returns as of 5/5/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
BNTX
4.27%
MSCI WORLD (^990100-USD-STRD)
4.83%
1-Year Return
BNTX
5.33%
MSCI WORLD (^990100-USD-STRD)
25.27%
3-Year Return
BNTX
7.70%
MSCI WORLD (^990100-USD-STRD)
64.57%
5-Year Return
BNTX
43.09%
MSCI WORLD (^990100-USD-STRD)
58.36%
Earnings Trends: BNTX
View MoreAnalyst Insights: BNTX
View MoreStatistics: BNTX
View MoreValuation Measures
As of 5/1/2026
-
Market Cap
25.12B
-
Enterprise Value
7.99B
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
7.01
-
Price/Book (mrq)
1.10
-
Enterprise Value/Revenue
2.24
-
Enterprise Value/EBITDA
32.70
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-39.59%
-
Return on Assets (ttm)
-3.56%
-
Return on Equity (ttm)
-5.88%
-
Revenue (ttm)
2.87B
-
Net Income Avi to Common (ttm)
-1.14B
-
Diluted EPS (ttm)
-5.61
Balance Sheet and Cash Flow
-
Total Cash (mrq)
13.74B
-
Total Debt/Equity (mrq)
1.39%
-
Levered Free Cash Flow (ttm)
-1.1B
Compare To: BNTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: BNTX
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: BNTX
View More-
BioNTech Earnings: Guidance Lower Than Expected, and Management To Step Down by Year-End
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
RatingPrice Target -
BioNTech Earnings: Guidance Lower Than Expected, and Management To Step Down by Year-End
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
RatingPrice Target -
BioNTech Earnings: Steady Progress in Next-Generation Oncology Pipeline; Guidance Raised
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
RatingPrice Target -
Covid Vaccine Market: CDC Advisory Committee Preserves Access but Removes Recommendation
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
RatingPrice Target
